Farnesyl pyrophosphate synthase Inhibitors
1 drugsAbout Farnesyl pyrophosphate synthase
Farnesyl pyrophosphate synthase (FPPS) is an enzyme in the isoprenoid pathway, producing molecules like cholesterol and ubiquinone. It catalyzes the formation of farnesyl pyrophosphate (FPP) from IPP, DMAPP and GPP, a key intermediate in synthesizing essential biomolecules.
FPPS is a drug target because inhibiting it can disrupt isoprenoid production, impacting cellular processes. Currently, there is no genetic evidence data available linking FPPS to specific diseases, limiting understanding of its role in disease pathology.
There is one FDA-approved drug, RECLAST (Novartis), targeting FPPS across 4 indications. RECLAST is a small molecule approved in 2007, representing the only approved drug in this space.
Strategic Insights
ℹ️ How we calculate- White space opportunity in Congenital Dyserythropoietic Anemia (CDA) with only 1 trials.
- phase3 represents biological uncertainty with 50% completion.
Top Farnesyl pyrophosphate synthase Drugs
Novartis is the only company with an approved drug (RECLAST) targeting FPPS.
The lack of competition suggests a high barrier to entry or an untapped market opportunity for new players.
Farnesyl pyrophosphate synthase Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Farnesyl pyrophosphate synthase, using small molecule modality.
Exploring alternative modalities like antibodies or peptides could provide differentiation and new therapeutic avenues.
Farnesyl pyrophosphate synthase Clinical Trials 106 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 17 | 8 | 3 | 6 | 73% |
| Phase 2 | 35 | 24 | 9 | 2 | 73% |
| Phase 3 | 21 | 13 | 4 | 4 | 76% |
| Phase 4 | 33 | 23 | 3 | 7 | 88% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved Farnesyl pyrophosphate synthase drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting Farnesyl pyrophosphate synthase. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
Farnesyl pyrophosphate synthase Drug Approval Timeline (2007 - 2007)
The first and only drug, RECLAST, was approved in 2007.
The approval timeline suggests a saturated market, requiring significant innovation for future entrants.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 57 clinical trials targeting Farnesyl pyrophosphate synthase.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities